(0.08%) 5 250.25 points
(0.01%) 39 647 points
(0.16%) 18 285 points
(0.09%) $78.33
(1.29%) $2.28
(-0.79%) $2 356.30
(-0.44%) $28.38
(0.24%) $1 009.60
(-0.03%) $0.928
(0.27%) $10.86
(0.01%) $0.799
(-0.90%) $91.84
@ $2.22
Issued: 14 Feb 2024 @ 09:33
Return: -9.46%
Previous signal: Feb 13 - 15:01
Previous signal:
Return: 1.14 %
Live Chart Being Loaded With Signals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...
Stats | |
---|---|
Today's Volume | 271 884 |
Average Volume | 472 603 |
Market Cap | 179.96M |
EPS | $0 ( 2024-03-05 ) |
Next earnings date | ( $-0.100 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.57 |
ATR14 | $0.00600 (0.30%) |
Volume Correlation
Compugen Ltd Correlation
10 Most Positive Correlations | |
---|---|
ENTG | 0.933 |
ADSE | 0.932 |
KOPN | 0.93 |
CTIC | 0.926 |
RMBL | 0.917 |
ALR | 0.916 |
MVIS | 0.914 |
MRAM | 0.913 |
NWLI | 0.912 |
ORGO | 0.912 |
10 Most Negative Correlations | |
---|---|
ULTA | -0.945 |
SBNYP | -0.915 |
HOLUU | -0.904 |
EMBCV | -0.899 |
TTCF | -0.889 |
OPTN | -0.888 |
CDAK | -0.884 |
CPRX | -0.88 |
PHCF | -0.87 |
BNIXU | -0.87 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Compugen Ltd Correlation - Currency/Commodity
Compugen Ltd Financials
Annual | 2023 |
Revenue: | $33.46M |
Gross Profit: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2023 |
Revenue: | $33.46M |
Gross Profit: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2022 |
Revenue: | $7.50M |
Gross Profit: | $6.53M (87.00 %) |
EPS: | $-0.390 |
FY | 2021 |
Revenue: | $6.00M |
Gross Profit: | $5.32M (88.67 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators